{{Rsnum
|rsid=2848716
|Gene=MICA
|Chromosome=6
|position=31420190
|Orientation=minus
|GMAF=0.1534
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 82.0 | 18.0 | 0.0
| HCB | 46.7 | 42.2 | 11.1
| JPT | 40.9 | 47.7 | 11.4
| YRI | 100.0 | 0.0 | 0.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 46.7 | 42.2 | 11.1
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2848716
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:16538176
|Annotation=Risk or phenotype-associated allele: C allele. Phenotype: The C allele of rs2848716 shows strong association with carbamazepine (CBZ)-induced Stevens-Johnson syndrome (SJS)/Toxic Epidermal Necrolysis (TEN, Lyell's syndrome). Study size: 204. Study population/ethnicity: 60 CBZ-induced SJS/TEN cases and 144 CBZ-tolerant controls of Chinese descent. Significance metric(s): p = 7.58x10(-17), Pc = 2.10x10(-14), OR = 6.86. Type of association: GN; PD; TOX; ADR.
|Drugs=carbamazepine
|Drug Classes=
|Diseases=Drug Hypersensitivity; Epidermal Necrolysis, Toxic; Stevens-Johnson Syndrome
|Curation Level=Curated
|PharmGKB Accession ID=PA165291957
}}

{{PharmGKB
|RSID=rs2848716
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:16538176
|Annotation=The C allele of this SNP has been associated with development of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in Chinese populations in response to carbamazepine treatment.
|Drugs=carbamazepine
|Drug Classes=
|Diseases=Epidermal Necrolysis, Toxic; Stevens-Johnson Syndrome
|Curation Level=Curated
|PharmGKB Accession ID=PA162316741
}}

{{PharmGKB
|RSID=rs2848716
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:16538176; Web Resource:http://www.fda.gov/cder/drug/InfoSheets/HCP/carbamazepineHCP.htm
|Annotation=This variant is associated with severe adverse reactions (Stevens Johnson syndrome and toxic epidermal necrolysis) of carbamazepine therapy.
|Drugs=carbamazepine
|Drug Classes=
|Diseases=Bipolar Disorder; Epidermal Necrolysis, Toxic; Epilepsy; Stevens-Johnson Syndrome
|Curation Level=Curated
|PharmGKB Accession ID=PA162263521
}}

{{PMID Auto
|PMID=21815799
|Title=Major histocompatibility complex class I chain-related gene polymorphisms: associated with susceptibility to Kawasaki disease and coronary artery aneurysms
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2848716
|overall_frequency_n=18
|overall_frequency_d=128
|overall_frequency=0.140625
|n_genomes=12
|n_genomes_annotated=0
|n_haplomes=14
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}